Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Workman

Showing results (281-290 of 315) with videos related to

Pageof 32
Sort By:
ACS Medicinal Chemistry Letters|January 8, 2019
Privileged Structures and Polypharmacology within and between Protein FamiliesJoshua Meyers, Nicola E A Chessum, Salyha Ali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2014
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumorsDebashis Sarker, Joo Ern Ang, Richard Baird, et al.
Molecular Cancer Therapeutics|July 9, 2009
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941Florence I Raynaud, Suzanne A Eccles, Sonal Patel, et al.
Cancer Research|June 19, 2007
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinasesFlorence I Raynaud, Suzanne Eccles, Paul A Clarke, et al.
Science Translational Medicine|June 3, 2011
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinomaNatsuko Suwaki, Elsa Vanhecke, Katelyn M Atkins, et al.
Medchemcomm|October 18, 2016
Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9Carl S Rye, Nicola E A Chessum, Scott Lamont, et al.
Journal of Medicinal Chemistry|April 5, 2023
HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other MalignanciesA Elisa Pasqua, Swee Y Sharp, Nicola E A Chessum, et al.
Molecular Cancer Therapeutics|April 14, 2007
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analoguesSwee Y Sharp, Chrisostomos Prodromou, Kathy Boxall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2012
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activityTimothy A Yap, Mike I Walton, Kyla M Grimshaw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2025
Correction: AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor ActivityTimothy A Yap, Mike I Walton, Kyla M Grimshaw, et al.
Pageof 32

Showing results (281-290 of 315) with videos related to

Sort By:
Pageof 32
ACS Medicinal Chemistry Letters|January 8, 2019
Privileged Structures and Polypharmacology within and between Protein FamiliesJoshua Meyers, Nicola E A Chessum, Salyha Ali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2014
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumorsDebashis Sarker, Joo Ern Ang, Richard Baird, et al.
Molecular Cancer Therapeutics|July 9, 2009
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941Florence I Raynaud, Suzanne A Eccles, Sonal Patel, et al.
Cancer Research|June 19, 2007
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinasesFlorence I Raynaud, Suzanne Eccles, Paul A Clarke, et al.
Science Translational Medicine|June 3, 2011
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinomaNatsuko Suwaki, Elsa Vanhecke, Katelyn M Atkins, et al.
Medchemcomm|October 18, 2016
Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9Carl S Rye, Nicola E A Chessum, Scott Lamont, et al.
Journal of Medicinal Chemistry|April 5, 2023
HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other MalignanciesA Elisa Pasqua, Swee Y Sharp, Nicola E A Chessum, et al.
Molecular Cancer Therapeutics|April 14, 2007
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analoguesSwee Y Sharp, Chrisostomos Prodromou, Kathy Boxall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2012
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activityTimothy A Yap, Mike I Walton, Kyla M Grimshaw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2025
Correction: AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor ActivityTimothy A Yap, Mike I Walton, Kyla M Grimshaw, et al.
Pageof 32